Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H7O6P.2Na.5H2O |
Molecular Weight | 306.1138 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Na+].[Na+].OCC(CO)OP([O-])([O-])=O
InChI
InChIKey=PEMUISUYOHQFQH-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2Na.5H2O/c4-1-3(2-5)9-10(6,7)8;;;;;;;/h3-5H,1-2H2,(H2,6,7,8);;;5*1H2/q;2*+1;;;;;/p-2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C3H9O6P |
Molecular Weight | 172.0737 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of
bile in human subjects with cholesterol gallstones in a short-term study
and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones
in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22383088 |
|||
Target ID: Protein phosphatase |
|||
Target ID: Glycerol-2-phosphatase |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1060200 |
Primary | Unknown Approved UseUnknown |
||
Primary | Glycophos Approved UseGlycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
Dose
Adults:
The recommended dosage is individual. The recommended daily dosage of
phosphate during intravenous nutrition would normally be 10-20 mmol. This can be
met by using 10-20 mL of GLYCOPHOS (Sodium glycerophosphate pentahydrate) added to the infusion solution or to the
admixture for which compatibility has been proved.
Children, Infants and Neonates:
The recommended dosage is individual. The recommended dose for children,
infants and neonates is 1.0-1.5 mmol/kg body weight/day.
Method of administration
Intravenous Infusion.
GLYCOPHOS must not be given undiluted. The infusion time should not be less than 8 hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1422975
Medium supplementation with beta-GP (Sodium 2-glycerophosphate) should not exceed 2 mM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:44:31 GMT 2023
by
admin
on
Sat Dec 16 10:44:31 GMT 2023
|
Record UNII |
5JIY5MMX0E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2735049
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
154804-51-0
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
5JIY5MMX0E
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
13408-09-8
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
DTXSID60158536
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
PRIMARY | |||
|
69881-75-0
Created by
admin on Sat Dec 16 10:44:31 GMT 2023 , Edited by admin on Sat Dec 16 10:44:31 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |